open access

Vol 6 (2021): Continuous Publishing
Letter to the Editor
Published online: 2021-11-26
Get Citation

Ocular involvement in mucormycosis during COVID-19 and post-COVID 19 syndrome: a new challenge in ophthalmology

Fernando Godin-Estrada1, Laura Alejandra Acevedo-Espitia2, Valentina Delgado, Michael Gregorio Ortega-Sierra3, Ivan David Lozada Martinez4
·
Ophthalmol J 2021;6:223-226.
Affiliations
  1. School of Medicine, Universidad el Bosque, Bogota, Colombia
  2. School of Medicine, Universidad de La Sabana, Chía, Colombia
  3. Medical and Surgical Research Center, Corporación Universitaria Rafael Nuñez, Cartagena, Colombia
  4. Grupo Prometheus y Biomedicina Aplicada a las Ciencias Clinicas, School of Medicine, Universidad de Cartagena, Cartagena, Colombia

open access

Vol 6 (2021): Continuous Publishing
LETTER TO THE EDITOR
Published online: 2021-11-26

Abstract

Not required.

Abstract

Not required.

Get Citation

Keywords

orbital diseases; COVID-19; orbital mucormycosis; post-COVID 19 syndrome

About this article
Title

Ocular involvement in mucormycosis during COVID-19 and post-COVID 19 syndrome: a new challenge in ophthalmology

Journal

Ophthalmology Journal

Issue

Vol 6 (2021): Continuous Publishing

Article type

Letter to the Editor

Pages

223-226

Published online

2021-11-26

Page views

5964

Article views/downloads

313

DOI

10.5603/OJ.2021.0036

Bibliographic record

Ophthalmol J 2021;6:223-226.

Keywords

orbital diseases
COVID-19
orbital mucormycosis
post-COVID 19 syndrome

Authors

Fernando Godin-Estrada
Laura Alejandra Acevedo-Espitia
Valentina Delgado
Michael Gregorio Ortega-Sierra
Ivan David Lozada Martinez

References (10)
  1. Mohammadi F, Badri M, Safari S, et al. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. BMC Infect Dis. 2021; 21(1): 906.
  2. Arora R, Goel R, Khanam S, et al. Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021 - A Preliminary Report from a Single Hospital. Clin Ophthalmol. 2021; 15: 3505–3514.
  3. Nair AG, Adulkar NG, D'Cunha L, et al. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Orbit. 2021; 40(6): 499–504.
  4. Palou EY, Ramos MA, Cherenfant E, et al. COVID-19 Associated Rhino-Orbital Mucormycosis Complicated by Gangrenous and Bone Necrosis-A Case Report from Honduras. Vaccines (Basel). 2021; 9(8).
  5. Garg R, Bharangar S, Gupta S, et al. Post Covid-19 Infection Presenting as Rhino-Orbital Mycosis. Indian J Otolaryngol Head Neck Surg. 2021 [Epub ahead of print]: 1–8.
  6. Mitra S, Janweja M, Sengupta A. Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control. Eur Arch Otorhinolaryngol. 2021 [Epub ahead of print].
  7. Desai EJ, Pandya A, Upadhya I, et al. Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients. Indian J Otolaryngol Head Neck Surg. 2021 [Epub ahead of print]: 1–5.
  8. Sharma S, Grover M, Bhargava S, et al. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021; 135(5): 442–447.
  9. González-Herazo MA, Silva-Muñoz DC, Guevara-Martínez PA, et al. Post-COVID 19 Neurological Syndrome: a fresh challenge in neurological management. Neurol Neurochir Pol. 2021; 55(4): 413–414.
  10. Camargo-Martínez W, Lozada-Martínez I, Escobar-Collazos A, et al. Post-COVID 19 neurological syndrome: Implications for sequelae's treatment. J Clin Neurosci. 2021; 88: 219–225.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Publisher: VM Media Group sp. z o.o., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 310 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl